Table 1 Patient demographics and baseline characteristics
Parameters | Nintedanib once-daily (n = 14) | Nintedanib twice-daily (n = 16) |
|---|---|---|
Median age, years (range) | 58.0 (41–74) | 59.5 (34–74) |
Sex, n (%) | Â | Â |
  Male | 9 (64) | 15 (94) |
  Female | 5 (36) | 1 (6) |
ECOG performance status, n (%) | Â | Â |
  0 | 2 (14) | 5 (31) |
  1 | 10 (71) | 10 (63) |
  2 | 1 (7) | 1 (6) |
  Unknown | 1 (7) | 0 |
Median time since diagnosis, days (range) | 733 (325–2,214) | 1,006 (229–2,968) |
  Prior treatment for CRC, n (%) |  |  |
  Chemotherapy | 14 (100) | 16 (100) |
  Radiotherapy | 4 (29) | 5 (31) |
  Surgery | 14 (100) | 16 (100) |
  Immunotherapy | 1a (7) | 0 |
  Hormone therapy | 1 (7) | 1 (6) |
Clinical stage at diagnosis, n (%) | Â | Â |
  Stage I | 0 | 2 (13) |
  Stage II | 1 (7) | 1 (6) |
  Stage III | 1 (7) | 7 (44) |
  Stage IV | 12 (86) | 6 (38) |
Location of metastatic sites,b n (%) | Â | Â |
  Lung | 5 (38) | 9 (56) |
  Liver | 10 (71) | 11 (69) |
  Lymph nodes | 6 (43) | 7 (44) |
  Bone | 1 (7) | 0 |
  Median number of metastatic sites, n (range) | 2 (1–4) | 2 (1–5) |